Evidence map›Paper›PMID 37768496›Full record

ReviewMolecular and cellular biochemistry2024

Physiological effects of ivabradine in heart failure and beyond.

Audra N Iness, Keyur M Shah, Rakesh C Kukreja

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Ion channel trafficking implications in heart failure.Frontiers in cardiovascular medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Audra N InessDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Keyur M ShahDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Rakesh C KukrejaDivision of Cardiology, Pauley Heart Center, Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. rakesh.kukreja@vcuhealth.org.
Virginia Commonwealth University · USBaylor College of Medicine · US

Funding

Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryonic Stem Cell-Derived ExosomesR01CA221813 · NCI · UNIVERSITY OF CENTRAL FLORIDA · PI KUKREJA, RAKESH C, SINGLA, DINENDER KUMAR · 2018 to 2024
$3.1M
BMP-7 Modulates Inflammation induced cell death in Diabetic Cardiac and Skeletal MuscleR01DK120866 · NIDDK · UNIVERSITY OF CENTRAL FLORIDA · PI KUKREJA, RAKESH C, SINGLA, DINENDER KUMAR · 2018 to 2021
$2.7M
ROS, Inflammation, and Cardioprotection in Type 2 DiabetesR01HL118808 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI KUKREJA, RAKESH C · 2013 to 2017
$2.5M
Congressionally Directed Medical Research Programs W81XWH-18-1-0308NCI NIH HHS R01 CA221813NHLBI NIH HHS R01 HL118808NHLBI NIH HHS RO1HL124366NIDDK NIH HHS R01 DK120866NIH HHS CA221813
6 · The paper itself

Abstract

Ivabradine is a pharmacologic agent that inhibits the funny current responsible for determining heart rate in the sinoatrial node. Ivabradine's clinical potential has been investigated in the context of heart failure since it is associated with reduced myocardial oxygen demand, enhanced diastolic filling, stroke volume, and coronary perfusion time; however, it is yet to demonstrate definitive mortality benefit. Alternative effects of ivabradine include modulation of the renin-angiotensin-aldosterone system, sympathetic activation, and endothelial function. Here, we review key clinical trials informing the clinical use of ivabradine and explore opportunities for leveraging its potential pleiotropic effects in other diseases, including treatment of hyperadrenergic states and mitigating complications of COVID-19 infection.

Indexed as

COVID-19Heart FailureIvabradineCardiovascular AgentsCOVID-19 Drug TreatmentHeart RateHumansRenin-Angiotensin SystemSARS-CoV-2Cardiovascular AgentsIvabradineFunny currentHeart failureIschemiaIvabradineSinoatrial node

Identifiers

PMID37768496
OpenAlexW4387115119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.